Out to chal­lenge Gilead­'s dai­ly pills, Vi­iv scores three-year da­ta on month­ly com­bo; Rigel bags $33M from Asia li­cens­ing deal

→ On the heels of an NDA sub­mis­sion, Vi­iv has post­ed longterm da­ta sup­port­ing its the­o­ry that an­oth­er one of its long-act­ing two-drug com­bos could work just as well as the dai­ly triplets of­fered by its big ri­val Gilead. In a Phase IIb tri­al, re­searchers found that at the three-year mark, 90% pa­tients re­ceiv­ing the in­jectable reg­i­men of cabote­gravir and rilpivirine every eight weeks re­mained vi­ral­ly sup­pressed; 83% of those on the four-week reg­i­men did. It echoes a set of Phase III re­sults the GSK sub­sidiary un­veiled in Au­gust, which Vi­iv says points to the com­bo’s po­ten­tial in “chang­ing HIV treat­ment from 365 dos­ing days per year, to just 12.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER